A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass.

OBJECTIVE This study investigated postoperative hemostasis of patients subjected to conventional protamine dosing compared with protamine dosing based on a pharmacokinetic (PK) model following cardiopulmonary bypass. DESIGN Retrospective case-control study. SETTING Tertiary university hospital. PARTICIPANTS Patients undergoing elective cardiac surgery with cardiopulmonary bypass. INTERVENTIONS In 56 patients, protamine was dosed in a fixed ratio (CD), while 62 patients received protamine based on the PK model. MEASUREMENTS AND MAIN RESULTS There was no difference in heparin administration (414±107 mg (CD) v 403±90 mg (PK); p = 0.54), whereas protamine dosing was considerably different with a protamine-to-heparin dosing ratio of 1.1±0.3 for the CD group and 0.5±0.1 for the PK group (p<0.001). The changes in activated coagulation time (ΔACT) values (ACT after protamine minus preoperative ACT;+17±77 s v+6±15 s; p = 0.31) were equal between groups. Yet, the thromboelastometric intrinsically activated coagulation test clotting time (CT; 250±76 s v 203±44 s; p<0.001) and intrinsically activated coagulation test without the heparin effect CT (275±105 v 198±32 s; p<0.001) were prolonged in the CD group. Median packed red blood cell transfusion (0 [0-2] v 0 [0-0]), fresh frozen plasma transfusion (1 [0-2] v 0 [0-0]), and platelet concentrate transfusion (0 [0-1] v 0 [0-0]) were different between the fixed ratio and PK group, respectively (all p<0.001). CONCLUSIONS This study showed that patient-tailored protamine dosing based on a PK model was associated with a reduction in protamine dosing, with better hemostatic test results when compared with fixed-ratio protamine dosing.

[1]  C. Boer,et al.  Calculating the Protamine Dose Necessary to Neutralize Heparin in All Patients Under All Circumstances. , 2016, Journal of cardiothoracic and vascular anesthesia.

[2]  J. van der Linden,et al.  An Adjusted Calculation Model Allows for Reduced Protamine Doses without Increasing Blood Loss in Cardiac Surgery , 2015, The Thoracic and Cardiovascular Surgeon.

[3]  M. Appelblad,et al.  Reversal of heparin after cardiac surgery: protamine titration using a statistical model. , 2015, Journal of cardiothoracic and vascular anesthesia.

[4]  Wei Lu,et al.  Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery , 2015, Journal of Translational Medicine.

[5]  M. Ozaki,et al.  Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery. , 2014, Journal of cardiothoracic and vascular anesthesia.

[6]  C. Boer,et al.  Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. , 2014, Journal of cardiothoracic and vascular anesthesia.

[7]  J. Gummert,et al.  Protamine Overdose and Its Impact on Coagulation, Bleeding, and Transfusions After Cardiopulmonary Bypass , 2014, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[8]  P. GayosoDiz,et al.  Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery. , 2013 .

[9]  V. Vogel,et al.  A novel method for the direct determination of heparin concentration during cardiopulmonary bypass surgery , 2013, Clinical Chemistry and Laboratory Medicine.

[10]  P. Wouters,et al.  Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. , 2013, European journal of anaesthesiology.

[11]  H. Zheng,et al.  Blood loss after cardiopulmonary bypass, standard vs titrated protamine: a meta-analysis. , 2013, The Netherlands journal of medicine.

[12]  F. Gude Sampedro,et al.  Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery. , 2013, The journal of extra-corporeal technology.

[13]  Howard K. Song,et al.  2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. , 2011, The Annals of thoracic surgery.

[14]  Howard K. Song,et al.  Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines , 2011 .

[15]  V. Nielsen,et al.  Protamine sulfate: crouching clot or hidden hemorrhage? , 2010, Anesthesia and analgesia.

[16]  N. Khan,et al.  The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph , 2010, European journal of anaesthesiology.

[17]  P. Innerhofer,et al.  Detection of Protamine and Heparin After Termination of Cardiopulmonary Bypass by Thrombelastometry (ROTEM®): Results of a Pilot Study , 2009, Anesthesia and analgesia.

[18]  F. Laduca,et al.  Assessing heparin neutralization following cardiac surgery: sensitivity of thrombin time-based assays versus protamine titration methods , 1999, Perfusion.

[19]  J. Weiler,et al.  Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. , 1997, Journal of cardiothoracic and vascular anesthesia.

[20]  K. Iwamoto,et al.  Disposition of tritium-labelled heparin in rats. , 1982, Journal of pharmacobio-dynamics.

[21]  T. Ryan,et al.  Reduced Protamine Dosage for Heparin Neutralization in Open‐Heart Operations , 1968, Circulation.

[22]  P. Olsson,et al.  The elimination from plasma of intravenous heparin. An experimental study on dogs and humans. , 2009, Acta medica Scandinavica.